Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
Objective: Clinical trials play an important role in the development of healthcare. However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. Therefore, this study aims to provide a comprehensive analysis of the registered trials related to anti-...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212813/full |
| _version_ | 1797629248712736768 |
|---|---|
| author | Zelei Dai Nian Li Jun Wang Chenfeng Tan Yonggang Zhang Lei Liu |
| author_facet | Zelei Dai Nian Li Jun Wang Chenfeng Tan Yonggang Zhang Lei Liu |
| author_sort | Zelei Dai |
| collection | DOAJ |
| description | Objective: Clinical trials play an important role in the development of healthcare. However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. Therefore, this study aims to provide a comprehensive analysis of the registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma on ClinicalTrials.gov.Methods: A search was conducted on the ClinicalTrials.gov database to identify all registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma up to 26 February 2023. The characteristics of the trials were examined, and the studied drugs, disease conditions, as well as details of trials with available results were analyzed. Publication status was assessed by a PubMed search using the ClinicalTrials.gov NCT number.Results: A total of 112 interventional clinical trials registered between 2015 and 2023 were included. Of the trials, 90 were carried out in Asia, 72 were in phase 2, and 31 trials had either companies or universities as sponsors/collaborators. The sample sizes across the trials varied greatly, with a median of 71.5 participants per trial. The majority of trials were recruiting participants, with only 6 had posted results. PD-1 inhibitors were preferred over PD-L1, and Toripalimab emerged as the most extensively studied drug. About one-third (33.9%) of the studies looked into recurrent/metastatic nasopharyngeal cancer.Conclusion: This study provides an overview of all registered trials of anti-PD-1/PD-L1 for NPC. It is needed to improve the completeness, outcome selection, randomization and masking of trials and to be transparent and timely in reporting of results. |
| first_indexed | 2024-03-11T10:50:39Z |
| format | Article |
| id | doaj.art-143a64d6051f4ed6ac7700b346555e50 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-11T10:50:39Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-143a64d6051f4ed6ac7700b346555e502023-11-13T17:53:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-11-011410.3389/fphar.2023.12128131212813Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.govZelei Dai0Nian Li1Jun Wang2Chenfeng Tan3Yonggang Zhang4Lei Liu5Division of Head and Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Administration, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Head and Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Head and Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Evidence Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, ChinaDivision of Head and Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaObjective: Clinical trials play an important role in the development of healthcare. However, the current status of clinical trials on anti-PD-1/PD-L1 for nasopharyngeal carcinoma remains unclear. Therefore, this study aims to provide a comprehensive analysis of the registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma on ClinicalTrials.gov.Methods: A search was conducted on the ClinicalTrials.gov database to identify all registered trials related to anti-PD-1/PD-L1 for nasopharyngeal carcinoma up to 26 February 2023. The characteristics of the trials were examined, and the studied drugs, disease conditions, as well as details of trials with available results were analyzed. Publication status was assessed by a PubMed search using the ClinicalTrials.gov NCT number.Results: A total of 112 interventional clinical trials registered between 2015 and 2023 were included. Of the trials, 90 were carried out in Asia, 72 were in phase 2, and 31 trials had either companies or universities as sponsors/collaborators. The sample sizes across the trials varied greatly, with a median of 71.5 participants per trial. The majority of trials were recruiting participants, with only 6 had posted results. PD-1 inhibitors were preferred over PD-L1, and Toripalimab emerged as the most extensively studied drug. About one-third (33.9%) of the studies looked into recurrent/metastatic nasopharyngeal cancer.Conclusion: This study provides an overview of all registered trials of anti-PD-1/PD-L1 for NPC. It is needed to improve the completeness, outcome selection, randomization and masking of trials and to be transparent and timely in reporting of results.https://www.frontiersin.org/articles/10.3389/fphar.2023.1212813/fullnasopharyngeal carcinomaanti-PD-1/PD-L1 antibodiesclinical trialtreatmentcomprehensive analysis |
| spellingShingle | Zelei Dai Nian Li Jun Wang Chenfeng Tan Yonggang Zhang Lei Liu Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov Frontiers in Pharmacology nasopharyngeal carcinoma anti-PD-1/PD-L1 antibodies clinical trial treatment comprehensive analysis |
| title | Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov |
| title_full | Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov |
| title_fullStr | Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov |
| title_full_unstemmed | Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov |
| title_short | Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov |
| title_sort | anti pd 1 pd l1 for nasopharyngeal carcinoma a comprehensive analysis of registered trials on clinicaltrials gov |
| topic | nasopharyngeal carcinoma anti-PD-1/PD-L1 antibodies clinical trial treatment comprehensive analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1212813/full |
| work_keys_str_mv | AT zeleidai antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov AT nianli antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov AT junwang antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov AT chenfengtan antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov AT yonggangzhang antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov AT leiliu antipd1pdl1fornasopharyngealcarcinomaacomprehensiveanalysisofregisteredtrialsonclinicaltrialsgov |